Bank of Marin Bancorp returns to profitability following strategic balance sheet restructuring
Bank of Marin Bancorp (NASDAQ:BMRC) reported a strong return to profitability for the first quarter of 2026 on Monday, posting net income of $8.5 million.
Bank of Marin Bancorp (NASDAQ:BMRC) reported a strong return to profitability for the first quarter of 2026 on Monday, posting net income of $8.5 million.
Johnson & Johnson (NYSE:JNJ) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu).
AbbVie (NYSE:ABBV) announced on Monday, April 27, 2026, that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for SKYRIZI (risankizumab-rzaa).
Norwood Financial (NASDAQ:NWFL), the parent company of Wayne Bank, announced its financial results for the first quarter of 2026 on Monday, a period defined by the successful closing and integration of Presence Bancshares.
Thermo Fisher Scientific (NYSE:TMO) announced on Monday that it has entered into a definitive agreement to sell its microbiology business to Astorg, a prominent pan-European private equity firm.
Jazz Pharmaceuticals (NASDAQ:JAZZ) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii).
CorMedix (NASDAQ:CRMD) announced positive topline results on Monday from the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for the prevention of invasive fungal diseases in adult allogeneic hematopoietic stem cell transplant (HSCT) patients.
Alterity Therapeutics (NASDAQ:ATHE) announced on Monday that it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a second Type C meeting regarding its ATH434 Phase 3 program.
Intellia Therapeutics (NASDAQ:NTLA) today announced positive topline results from its pivotal Phase 3 HAELO clinical trial evaluating lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR-based gene editing therapy for patients with hereditary angioedema (HAE).
Purple Biotech (NASDAQ:PPBT) released promising preclinical data on Monday for its lead therapeutic candidate, IM1240, demonstrating consistent anti-tumor activity across seven distinct patient-derived tumor samples.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
